CADL Up as FDA Grants RMAT Status to CAN-2409 in Prostate Cancer

Candel Therapeutics (CADL) announced that the FDA has granted the Regenerative Medicine Advanced Therapy (RMAT) designation to its investigational adenovirus immunotherapy candidate, CAN-2409 (aglatimagene besadenovec), for treating newly diagnosed localized prostate cancer in patients with intermediate-to-high-risk of the disease.The RMAT tag was granted based on positive data from a phase III study, which evaluated the safety and efficacy of CAN-2409+prodrug (valacyclovir)+standard of care (SOC) radiation ...